Daewoong Pharmaceutical made an announcement on Jan. 14 that it signed a partnership agreement with A2A Pharmaceuticals, Inc. (A2A), a U.S. bio company, on Jan. 12.
Through this contract, A2A is planning to design new compounds by utilizing SCULPT, a new drug design platform that combines artificial intelligence (AI), and Daewoong Pharmaceutical plans to develop new anti-cancer drugs by synthesizing and evaluating materials based on this structure.
A2A's SCULPT builds a library of target-based compounds by analyzing the structure of cancer-causing targets in detail through self-development technology and designing hundreds of millions of original substances suitable for targets.
And it is a drug discovery platform that can screen objects optimized for targets by predicting the binding and pharmacology of the material with artificial intelligence learning.
Daewoong Pharmaceutical expects to improve its chances of successful anti-cancer drug development and secure a new pipeline in the field of cancer by discovering the best anti-cancer drug candidate materials through SCULPT.
It is also predicted that the search for candidate materials through the use of AI platform will save time and money invested in new drug development.
"By applying research and development capabilities of Daewoong Pharmaceutical to A2A’s SCULPT platform, we expect to further enhance the development competitiveness of new anti-cancer drugs," Daewoong Pharmaceutical CEO Jeon Seung-ho said.
"We will make our utmost efforts to ensure that the open collaboration between Daewoong Pharmaceutical and A2A will be a representative success case in developing new AI-based drugs," he added.
